Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$16.32

-1.51 (-8.47%)

07:34
06/03/19
06/03
07:34
06/03/19
07:34

Iovance Biotherapeutics price target raised to $30 from $25 at Oppenheimer

Oppenheimer analyst Mark Breidenbach raised his price target for Iovance Biotherapeutics to $30 from $25 after the company presented updated results from its InnovaTIL-01 and -04 trials that were "clear highlights" of the ASCO meeting. The analyst believes the growing durability substantially improves the commercial profile of TIL therapy and based on the data, Breidenbach is increasing Probability of Success for both programs. He reiterates an Outperform rating on the shares.

  • 04

    Jun

  • 10

    Jun

  • 19

    Jun

  • 26

    Jun

IOVA Iovance Biotherapeutics
$16.32

-1.51 (-8.47%)

05/16/19
BARD
05/16/19
NO CHANGE
Target $34
BARD
Outperform
Iovance Biotherapeutics price target raised to $34 from $29 at Baird
Baird analyst Madhu Kumar raised his price target for Iovance Biotherapeutics to $34 from $29 and maintained an Outperform rating, citing increased tumor-infiltrading lymphocyte technology conviction on ASCO abstracts in cervical cancer and metastatic melanoma. The abstracts for Phase 2 data for TIL technology increases his conviction in Iova's TILs, particularly in cervical cancer, the analyst says in a research note.
05/23/19
WELS
05/23/19
NO CHANGE
Target $32
WELS
Outperform
Iovance Biotherapeutics price target raised to $32 from $23 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Iovance Biotherapeutics to $32 from $23 following FDA breakthrough therapy designation for its TIL cell therapy LN-145 in cervical cancer. With ongoing pivotal development in melanoma, the analyst sees a second potential accelerated path to market with breakthrough therapy designation in cervical cancer and sees upside potential to further regulatory update on LN145. Birchenough reiterates an Outperform rating on the shares.
06/02/19
PIPR
06/02/19
NO CHANGE
Target $20
PIPR
Overweight
Iovance best positioned cell therapy in solid tumors, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro notes that Iovance Biotherapeutics provided "positive" updates from cohort 2 of lifileucel's melanoma study and LN-145's cervical cancer trial. The analyst notes that response rates continue to "impress" and importantly responses continue to look to be durable. Overall, a "very positive" update that Catanzaro thinks bodes well for upcoming discussions with the FDA on LN-145's regulatory path in cervical cancer. He reiterates an Overweight rating and $20 price target on the shares, as he views Iovance as the best-positioned cell therapy in solid tumors.
06/03/19
HCWC
06/03/19
NO CHANGE
Target $32
HCWC
Buy
Iovance Biotherapeutics price target raised to $32 from $26 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis raised his price target for Iovance Biotherapeutics to $32 from $26 saying the company's TIL therapy-mediated anti-tumor effects validate further clinical and market development. Iovance's TIL products, LN-144 and LN-145, are continuing to deliver significant clinical promise in metastatic melanoma and metastatic cervical cancer, and investors are starting to recognize and reward it, Pantginis tells investors in a research note. He keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

LRCX

Lam Research

$231.75

-3.16 (-1.35%)

15:34
10/23/19
10/23
15:34
10/23/19
15:34
Options
Lam Research options imply 8.3% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Nov

  • 19

    Nov

  • 20

    Nov

15:31
10/23/19
10/23
15:31
10/23/19
15:31
Conference/Events
Morgan Stanley oil/gas E&P analysts to hold an analyst/industry conference call »

Analysts, along with…

POAI

Predictive Oncology

$0.41

-0.01 (-2.38%)

15:25
10/23/19
10/23
15:25
10/23/19
15:25
Conference/Events
Predictive Oncology to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

MU

Micron

$44.56

-0.12 (-0.27%)

15:23
10/23/19
10/23
15:23
10/23/19
15:23
Recommendations
Micron analyst commentary  »

Micron files annual…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 06

    Nov

  • 20

    Nov

NSC

Norfolk Southern

$184.63

-4.22 (-2.23%)

15:22
10/23/19
10/23
15:22
10/23/19
15:22
Downgrade
Norfolk Southern rating change  »

Norfolk Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

EBAY

eBay

$39.00

0.03 (0.08%)

15:19
10/23/19
10/23
15:19
10/23/19
15:19
Options
EBay options imply 8.7% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 29

    Oct

GOGO

Gogo

$5.99

0.08 (1.35%)

15:18
10/23/19
10/23
15:18
10/23/19
15:18
Hot Stocks
Gogo AVANCE platform exceeds 175,000 business aviation flights »

Gogo Business Aviation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 20

    Nov

FSV

FirstService

$96.64

-8.71 (-8.27%)

15:18
10/23/19
10/23
15:18
10/23/19
15:18
Earnings
FirstService reports Q3 adjusted EPS 92c, consensus $1.03 »

Earlier, FirstService…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
10/23/19
10/23
15:17
10/23/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
10/23/19
10/23
15:16
10/23/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSV

FirstService

$96.64

-8.71 (-8.27%)

15:15
10/23/19
10/23
15:15
10/23/19
15:15
Earnings
Correction: FirstService reports Q3 adjusted EPS 92c, consensus $1.03 »

Earlier, FirstService…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

FSV

FirstService

$96.64

-8.71 (-8.27%)

15:13
10/23/19
10/23
15:13
10/23/19
15:13
Recommendations
FirstService analyst commentary  »

FirstService estimates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

15:12
10/23/19
10/23
15:12
10/23/19
15:12
Conference/Events
Morgan Stanley financial services analysts hold analyst/industry conference call »

Financial Analysts Cyprys…

MSFT

Microsoft

$136.19

-0.2 (-0.15%)

15:07
10/23/19
10/23
15:07
10/23/19
15:07
On The Fly
Fly Intel: What to watch in Microsoft earnings report »

Microsoft (MSFT) is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 06

    Nov

  • 14

    Nov

  • 21

    Nov

XOM

Exxon Mobil

$69.49

0.38 (0.55%)

15:06
10/23/19
10/23
15:06
10/23/19
15:06
Hot Stocks
Qilak LNG executes heads of agreement with ExxonMobil for natural gas »

Qilak LNG, a Lloyds…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

XLNX

Xilinx

$93.83

-2.18 (-2.27%)

15:04
10/23/19
10/23
15:04
10/23/19
15:04
Options
Xilinx options imply 11.9% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 20

    Nov

FTNW

FTE Networks

$1.15

0.28 (32.18%)

14:52
10/23/19
10/23
14:52
10/23/19
14:52
Hot Stocks
Breaking Hot Stocks news story on FTE Networks »

FTE Networks Inc trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$254.68

-0.94 (-0.37%)

14:49
10/23/19
10/23
14:49
10/23/19
14:49
Options
Tesla options imply 11.9% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

KR

Kroger

$24.96

0.1 (0.40%)

14:45
10/23/19
10/23
14:45
10/23/19
14:45
Options
Kroger call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

14:45
10/23/19
10/23
14:45
10/23/19
14:45
General news
Treasury's $41 B 5-year auction was well supported »

Treasury's $41 B…

GSK

GlaxoSmithKline

$43.20

0.69 (1.62%)

, MYGN

Myriad Genetics

$32.14

-0.15 (-0.46%)

14:38
10/23/19
10/23
14:38
10/23/19
14:38
Hot Stocks
FDA approves niraparib for HRD-positive advanced ovarian cancer »

On October 23, the Food…

GSK

GlaxoSmithKline

$43.20

0.69 (1.62%)

MYGN

Myriad Genetics

$32.14

-0.15 (-0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

  • 30

    Oct

  • 06

    Nov

  • 13

    Nov

  • 07

    Dec

TSLA

Tesla

$253.92

-1.7 (-0.67%)

14:27
10/23/19
10/23
14:27
10/23/19
14:27
On The Fly
Fly Intel: What to watch in Tesla earnings report »

Tesla (TSLA) is scheduled…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

14:25
10/23/19
10/23
14:25
10/23/19
14:25
Conference/Events
Senate Caucus on International Narcotics Control holds a hearing »

The Caucus holds a…

ALKS

Alkermes

$19.30

0.88 (4.78%)

14:22
10/23/19
10/23
14:22
10/23/19
14:22
Recommendations
Alkermes analyst commentary  »

Alkermes making some…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

TSLA

Tesla

$253.68

-1.94 (-0.76%)

14:22
10/23/19
10/23
14:22
10/23/19
14:22
Periodicals
Tesla sued over Model S door handle malfunction, CCN says »

The family of a man who…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.